Amarin Corp Plc (AMRN)

[sts66]

Jesus H....I cannot believe Niacin is still even allowed to be sold based on the SAEs from that trial - it can cause diabetes!

Effects on Other Adverse Events

Assignment to niacin–laropiprant, as compared with assignment to placebo, was associated with a highly significant excess of participants with fatal or nonfatal serious adverse events (7137 [55.6%] vs. 6762 [52.7%], P<0.001), with many participants having more than one serious adverse event (Table S5 in Supplementary Appendix 1). The largest excesses in serious adverse events (nonfatal and fatal combined) were related to effects on glucose metabolism (Table 2Table 2Effects of Niacin–Laropiprant on Selected Serious Adverse Events and Diabetes., and Table S6 in Supplementary Appendix 1). In an analysis of the 8299 participants who had diabetes at the time of randomization, assignment to niacin–laropiprant, as compared with assignment to placebo, was associated with a 55% proportional increase in disturbances in diabetes control that were considered to be serious, most of which led to hospitalization (11.1% vs. 7.5%, P<0.001). In an analysis of the 17,374 participants who did not have diabetes at the time of randomization, assignment to niacin–laropiprant, as compared with assignment to placebo, was associated with a 32% proportional increase in the diagnosis of diabetes (5.7% vs. 4.3%, P<0.001).